63
In band
Moving averages
SMA 200$1.19-16.34%
Company profile
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplantation (BMT) or a type of cell therapy, and for other adoptive cell therapies. The company is headquartered in New York, New York.
SectorHealthcare
IndustryBiotechnology
Market cap$32.63M
P/E ratio2.971
EPS$0.35
Beta0.024
Dividend yield0.00%
52-week high$1.81
52-week low$0.74
Similar stocks in Biotechnology
BNTX
BioNTech SE
RSI 52
VRTX
Vertex Pharmaceuticals Inc
RSI 64
CRSP
CRISPR Therapeutics AG
RSI 54
IOVA
Iovance Biotherapeutics Inc
RSI 66
RXRX
Recursion Pharmaceuticals Inc - Class A
RSI 51
MRNA
Moderna Inc
RSI 67
VKTX
Viking Therapeutics Inc
RSI 49
SRPT
Sarepta Therapeutics Inc
RSI 67
EDIT
Editas Medicine Inc
RSI 52
NVAX
Novavax Inc
RSI 72
RSI alerts for ATNM
Get an email the moment Actinium Pharmaceuticals Inc crosses into oversold or overbought territory. Nothing else, ever.
Add alertData last updated 16 August 2026 at 2:23 AM EDT